Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Open Access
- 28 August 2015
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136910
Abstract
We performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials evaluating suvorexant for primary insomnia. Relevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations through June 27, 2015. We performed a systematic review and meta-analysis of suvorexant trial efficacy and safety outcomes. The primary efficacy outcomes were either subjective total sleep time (sTST) or subjective time-to-sleep onset (sTSO) at 1 month. The secondary outcomes were other efficacy outcomes, discontinuation rate, and individual adverse events. The risk ratio, number-needed-to-treat/harm, and weighted mean difference (WMD) and 95% confidence intervals (CI) based on a random effects model were calculated. The computerized literature database search initially yielded 48 results, from which 37 articles were excluded following a review of titles and abstracts and another eight review articles after full-text review. Thus, we identified 4 trials that included a total of 3,076 patients. Suvorexant was superior to placebo with regard to the two primary efficacy outcomes (sTST: WMD = −20.16, 95% CI = −25.01 to −15.30, 1889 patients, 3 trials, sTSO: WMD = −7.62, 95% CI = −11.03 to −4.21, 1889 patients, 3 trials) and was not different from placebo in trial discontinuations. Suvorexant caused a higher incidence than placebo of at least one side effects, abnormal dreams, somnolence, excessive daytime sleepiness/sedation, fatigue, dry mouth, and rebound insomnia. Our analysis of published trial results suggests that suvorexant is effective in treating primary insomnia and is well-tolerated.Keywords
This publication has 21 references indexed in Scilit:
- LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacyFrontiers in Neuroscience, 2014
- Insomnia Comorbid to Severe Psychiatric IllnessSleep Medicine Clinics, 2013
- Understanding the Sleep-Wake Cycle: Sleep, Insomnia, and the Orexin SystemThe Journal of Clinical Psychiatry, 2013
- Orexin receptor antagonism for treatment of insomniaNeurology, 2012
- Benzodiazepines revisited—will we ever learn?Addiction, 2011
- Benzodiazepine Use and DrivingThe Journal of Clinical Psychiatry, 2009
- Primary insomnia: a risk factor to develop depression?Journal of Affective Disorders, 2003
- Validation of the Insomnia Severity Index as an outcome measure for insomnia researchSleep Medicine, 2001
- The benzodiazepine withdrawal symptom questionnaireJournal of Affective Disorders, 1990
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986